GlassScriptPhysician profile
Hogai G Nassery
NPI 1598860298
$3,707.70
in general payments reported to CMS, 2019-2025
42 companies · $856 in 2025
The $856 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $727 · 2021: $696 · 2022: $110 · 2023: $597 · 2024: $611 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $487.38 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Gilead Sciences, INC. | $476.01 | 2020-2025 | |
| Lilly USA, LLC | $365.50 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Viiv Healthcare Company | $329.01 | 2020-2025 | Apretude, Rukobia, Cabenuva |
| Amgen INC. | $232.41 | 2020-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $191.07 | 2020-2025 | Pifeltro, Delstrigo |
| Abbvie INC. | $140.54 | 2020-2023 | |
| Janssen Biotech, INC. | $140.06 | 2019-2023 | Symtuza |
| Esperion Therapeutics, INC. | $130.91 | 2020-2025 | Nexletol |
| Theratechnologies INC. | $82.46 | 2019-2025 | Trogarzo, Egrifta |
| Medtronic, INC. | $76.19 | 2024-2025 | Minimed 780g |
| Allergan, INC. | $65.63 | 2019-2020 | |
| Dexcom, INC. | $60.44 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $59.46 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $57.61 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hogai Nassery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.